HaematologySickle Cell Disease

CRISPR and Gene Therapy: From Approval to Access

The first CRISPR medicine is approved. Only 64 patients received it all year. Why?

SR-2026-012

EditorMara Voss

CopywritersEditorial Team

Coming Soon

CRISPR and Gene Therapy: From Approval to Access

The first CRISPR medicine is approved. Only 64 patients received it all year. Why?

Why We Are Covering This

Casgevy is the first CRISPR medicine ever approved and a genuine scientific milestone. Yet only 64 patients received it in its entire first full year on market. The access failure is the story the approval headlines missed.

What to Expect

You will understand exactly where the manufacturing and reimbursement bottlenecks are, how payer annuity models are structured to address curative therapy economics, and what the realistic path to scale looks like.

Be first when this report publishes

The Life Science Feed briefing covers every major trial readout, approval, and pipeline shift, weekly.

Get the briefing first

thelifesciencefeed.com · Special Report

SR-2026-01207/26

Lymphoma

Liso-Cel Delivers Durable OS Benefit in R/R LBCL, Redefining Treatment

Lisocabtagene maraleucel (liso-cel) significantly extended overall survival in relapsed/refractory large B-cell lymphoma, establishing a new benchmark for second-line therapy.

Immune Thrombocytopenia

Monoclonal Antibodies May Complicate Transfusion Testing

Monoclonal antibodies, particularly IgG4 anti-CD47, may induce erythrophagocytosis and interfere with transfusion compatibility testing, posing a challenge for patient management.

Sickle Cell Disease

Blood Transfusion Safety: Pathogen Inactivation Reduces Transfusion-Transmitted Infections

Modern blood transfusion practices, including pathogen inactivation, have significantly reduced the risk of transfusion-transmitted infections, improving patient safety.

Leukemia

EHA 2026

Chemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)

Chemotherapy-free regimens for pediatric acute promyelocytic leukemia (APL) demonstrate superior efficacy and reduced toxicity compared to traditional chemotherapy.

CRISPR and Gene Therapy: From Approval to Access

CRISPR and Gene Therapy: From Approval to Access

Be first when this report publishes

Related Articles